Mirum Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) on December 16, 2022. The report discloses changes to the Company's Board of Directors, specifically the resignation of a director and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
- Director Resignation: Carol L. Brosgart, M.D., resigned as a director and member of the Nominating and Corporate Governance Committee, effective December 19, 2022. The resignation was not due to any dispute with the Company. She will transition to a role as senior advisor in science and policy.
- Director Appointment: Lon Cardon, Ph.D., FMedSci, was appointed to the Board effective December 19, 2022. He serves as a Class I director with a term expiring at the 2023 Annual Meeting of Stockholders.
- Committee Assignment: Dr. Cardon will serve on the Nominating and Corporate Governance Committee, succeeding Dr. Brosgart.
Compensation and Outlook
Dr. Cardon's compensation package includes:
- Stock Options: An initial grant of 34,000 shares vesting in three equal annual installments. Future annual grants of 17,000 shares are eligible commencing with the 2023 Annual Meeting.
- Cash Retainer: An annual cash retainer of $40,000 for Board service and $4,000 for committee service, pro-rated for 2022.
The filing contains no specific financial guidance, risk factors, or contingencies beyond standard indemnification agreements.
Investor Verification Checklist
- Verify the effective date of Dr. Brosgart's resignation and her new advisory role.
- Confirm Dr. Cardon's background and qualifications as a new Class I director.
- Review the vesting schedule for the 34,000 initial stock options granted to Dr. Cardon.
- Check the Company's Non-Employee Director Compensation Policy for details on pro-rating and future grants.